Paul Edick, CEO of Durata Therapeutics, Inc., bought 3,000 shares of Durata Therapeutics, Inc. (Stock Symbol: DRTX) at $45.70 per share for a total amount of $15.3 thousand on June 12, 2014.
Durata Therapeutics, Inc. is headquartered in Chicago, Illinois.
On 06/17/2014, Durata Therapeutics, Inc. announced today that members of the executive team will participate in three upcoming investor conferences. Paul R. Edick, Chief Executive Officer, will participate in the ROTH Resources Corporate Access Day on June 24 in London, England.Corey Fishman, Chief Operating Officer and Chief Financial Officer, will present at the JMP Healthcare Conference on June 24 at 9:30am EDT in New York, New York. Mr. Fishman will also participate in the Janney Capital Markets Healthcare Corporate Access Day on June 26 in Boston, Massachusetts.
On 05/08/2014, Durata Therapeutics, Inc. announced its latest quarterly results. “The first quarter of 2014 ended on a high note with the unanimous recommendation by the FDA’s Anti-Infective Drugs Advisory Committee for the approval of Dalvance,” said Paul R. Edick, CEO of Durata Therapeutics. “We are very focused on several major milestones, which include preparing for the May 26th action date for the FDA’s review of our NDA and an anticipated launch of Dalvance in the third quarter of 2014, as well as advancing additional studies of dalbavancin, among other initiatives.”
According to Capital IQ, Durata Therapeutics, Inc. has a market cap of $441.17 million, an enterprise value of $424.65 million.
Durata Therapeutics, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Its principal product includes dalbavancin, an intravenous antibiotic product candidate, which has completed Phase 3 clinical trials for the treatment of patients with acute bacterial skin and skin structure infections. The company was founded in 2009 and is headquartered in Chicago, Illinois.
Paul Edick’s most recent annual compensation from Durata Therapeutics is a salary of $468,802, $701,705 in other compensation, and a total compensation of $1,170,510. Mr. Edick is 59 years old.
According to his biography, Mr. Paul R. Edick serves as Chief Executive Officer, Director of Durata Therapeutics Inc. From 2008 to 2010, Mr. Edick served as chief executive officer of GANIC Pharmaceuticals, Inc. From 2006 to 2008, Mr. Edick served as chief executive officer of MedPointe Inc. until its acquisition by Meda AB. Mr. Edick also serves as a member of the board of directors of Newlink Genetics Corporation and Circassia Inc. From 2008 to 2011, Mr. Edick served as Chairman of the board of directors of LifeCycle Pharma A/S. Mr. Edick holds a B.A. in Psychology from Hamilton College in Clinton, New York. We believe that Mr. Edick’s extensive pharmaceutical industry experience with companies at various stages of development give him the qualifications and skills to serve as a director.
All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com .
About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.